ERBB2 and cancer: In the MY PATHWAY basket trial, trastuzumab + pertuzumab led to response rates for patients with pancreatic (22%), biliary (29%), and colorectal (38%) cancers with HER2 amplifications, suggesting it may have efficacy for HER-2 amplified ampullary adenocarcinoma [63].